Cardio · Intelligence Hub
Cardio intelligence
A live operating dashboard for this beat — capital flow, research pulse, regulatory shifts, ecosystem moves, and the velocity of every ingested signal.
Capital flow
1rounds
Research pulse
3studies
Policy shifts
2updates
Product launches
3shipped
Capital
Capital flow
- Funding
Research
Research pulse
Business Wire / Calibrate
Calibrate's 4th annual results report: members achieve 19% avg weight loss over 3 years via GLP-1 + ILIJACC (peer-reviewed)
SELECT trial sex subgroup in JACC: semaglutide reduces MACE in both sexes; women face higher baseline riskJACC (peer-reviewed)
STEP-HFpEF pooled sex analysis: semaglutide drives greater weight loss in women (-9.6%) vs men (-7.2%)Editorial · Cardiovascular
Semaglutide in obesity-related HFpEF: sex-stratified efficacy
Editorial · Cardiovascular
Semaglutide CV outcomes by sex in SELECT (n=17,604)
Regulatory
Watchlist & policy
Active watchlist
- CMS: menopause telehealth coverageactive
- FDA: PCOS diagnostic criteriapending
- EU MDR: fertility device reclass.watch
Policy signals · 2
- Circulation (AHA Journals) · Feb 1AHA Circulation 2025 Go Red issue calls for mandatory sex-disaggregated cardiovascular data
- FDA Press Announcement · Dec 20FDA approves Zepbound (tirzepatide) as first drug for obstructive sleep apnea in adults with obesity
Ecosystem
Ecosystem velocity
Organizations indexed
23
15 startups · 0 funds
Events this cycle
2
0 first-party
Total signals
10
ingested via RSS + editorial